(Q37016116)

17 August 2017

1 reference

title

Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen (English)

1 reference

17 August 2017

James A Simon

1

1 reference

17 August 2017

Michael C Snabes

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

2005-2020

1 reference

Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Clinical practice. Management of menopausal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Hot flashes: epidemiology and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Menopausal symptoms in older women and the effects of treatment with hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Growing, evolving HIV/AIDS pandemic is producing social and economic fallout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Symptom experience after discontinuing use of estrogen plus progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Discontinuation of postmenopausal hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Estrogen therapy and coronary-artery calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Estrogen receptors and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Breast cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

National use of postmenopausal hormone therapy: annual trends and response to recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

The decrease in breast-cancer incidence in 2003 in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Use of alternative therapies for menopause symptoms: results of a population-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Vasomotor symptom relief versus unwanted effects: role of estrogen dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

The rationale for low-dose hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Transdermal hormone therapy: gels and patches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Evidence from randomised trials on the long-term effects of hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Estrogen carcinogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Breast cancer risk with postmenopausal hormonal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Low-dosage esterified estrogens opposed by progestin at 6-month intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Hormone therapy to prevent disease and prolong life in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Rationale for use of lower estrogen doses for postmenopausal hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Publishing the results of the estrogen-only arm of WHI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Clinical trial of the estradiol vaginal ring in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, contro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.2005

10.1517/13543784.16.12.2005

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference